Capecitabine containing-regimen

Description Results NMA

capecitabine 1250 mg/m(2) orally bid days 1-14 (n=-9)

vs.

vinorelbine 30 mg/m(2) i.v. days 1 and 8, both given every 3 weeks (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

intermittent oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period) (n=-9)

vs.

intravenous CMF (cyclophosphamide. methotrexate, 5-fluorouracil [5-FU]) administered every three weeks (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

capecitabine, + medroxyprogesterone acetate (MPA) + cyclophosphamide (n=-9)

vs.

5-fluorouracil + adriamycin + CPA) plus MPA (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

three cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (n=753)

vs.

three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (n=747)

open-label

Sample size: 753/747

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles (n=-9)

vs.

docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1 (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

21-day cycles of oral capecitabine 1250 mg/m2 twice daily, on Days 1-14, plus docetaxel 75 mg/m2 Day 1 (n=255)

vs.

docetaxel 100 mg/m2 on Day 1 (n=256)

Sample size: 255/256

Primary endpoint:

FU duration:

(n=511)

vs.

(n=0)

Sample size: 511/0

Primary endpoint:

FU duration:

21-day cycles of oral capecitabine 1,250 mg/m(2) twice daily on days 1 to 14 plus docetaxel 75 mg/m(2) on day 1 (n=255)

vs.

docetaxel 100 mg/m(2) on day 1 (n=256)

Sample size: 255/256

Primary endpoint:

FU duration:

intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, (22 patients)) (n=-9)

vs.

i.v. paclitaxel (175 mg m(-2), (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: